NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market on Monday a 71 percent drop in revenues for its fourth quarter.

The San Diego-based molecular diagnostics firm posted $47,000 in revenues for the three months ended Dec. 31, 2013, down from $163,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.